PROEHL GERALD T - 09 Jan 2026 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Reporting relationship: Director
Issuer ticker: TENX
Reported as of: 09 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jan 2026, 20:46:39 UTC
Prior SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ S. Halle Vakani, as Attorney-in-Fact

Key filing fact

PROEHL GERALD T filed Form 4 for TENAX THERAPEUTICS, INC. (TENX) on 13 Jan 2026.

Key facts

This page summarizes PROEHL GERALD T's Form 4 filing for TENAX THERAPEUTICS, INC. (TENX).
1 reported transaction and 9 derivative rows are listed below.
Accepted by SEC: 13 Jan 2026, 20:46.

Change

Previous filing in this sequence was filed on 06 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001279191 Primary reporting owner

PROEHL GERALD T

Relationship: Director
Address: 101 GLEN LENNOX DRIVE SUITE 300, CHAPEL HILL
Signature: /s/ S. Halle Vakani, as Attorney-in-Fact
Signature date: 13 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TENX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,667
Date: 09 Jan 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TENX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +3,000
Change %: +11%
Price: $0.000000
Shares after: 30,000
Date: 09 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $13.30

TENX holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1
Date: 09 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1
Exercise price: $9968.00

TENX holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1
Date: 09 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1
Exercise price: $1056.00

TENX holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4
Date: 09 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4
Exercise price: $3200.00

TENX holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 4
Date: 09 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4
Exercise price: $992.00

TENX holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 100,000
Date: 09 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $5.94

TENX holding Derivative

Stock Option (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 80,000
Date: 09 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 80,000
Exercise price: $5.75

TENX holding Derivative

Pre-Funded Warrant

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 31,654
Date: 09 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 31,654
Exercise price: $0.0100
Footnotes: F1

TENX holding Derivative

Warrant

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 16,660
Date: 09 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,660
Exercise price: $4.50
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The pre-funded warrant has no expiration date.

Footnote F2

The warrant will expire on the earlier of (i) thirty (30) trading days following the date of the Issuer's initial public announcement of topline data from its Phase 3 LEVEL Study (LEVosimendan to Improve Exercise Limitation in PH-HFpEF Patients) (NCT05983250 ) (the "Topline Data Announcement"); (ii) proportionally upon the exercise of the Reporting Person's pre-funded warrant issued on August 8, 2024, if such exercise is prior to the Topline Data Announcement; and (iii) August 8, 2029.